GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ — I-Mab (“I-Mab” or the “Firm”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical firm dedicated to the invention, improvement, and commercialization…
- Friday, September 22, 2023
GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ — I-Mab (“I-Mab” or the “Firm”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical firm dedicated to the invention, improvement, and commercialization…